Another concern regarding PR agonist therapies is that although progesterone in combination with estrogen inhibits estrogen-induced proliferation [1, 2], progesterone alone is a mitogen in breast cancer [56], and 10 nM progesterone leads to robust proliferation in ER+/PR+ human tumor explants [57]. Here, ESR1 is linked to breast cancer.